Editorial: methotrexate in patients with Crohn's disease refractory to anti-TNF therapy-moving backwards yet forward?
- PMID: 33745173
- DOI: 10.1111/apt.16327
Editorial: methotrexate in patients with Crohn's disease refractory to anti-TNF therapy-moving backwards yet forward?
Comment on
-
Effectiveness and safety of methotrexate monotherapy in patients with Crohn's disease refractory to anti-TNF-α: results from the ENEIDA registry.Aliment Pharmacol Ther. 2021 May;53(9):1021-1029. doi: 10.1111/apt.16315. Epub 2021 Mar 14. Aliment Pharmacol Ther. 2021. PMID: 33715177
References
REFERENCES
-
- Peyrin-Biroulet L, Loftus EV Jr, Colombel J-F, Sandborn WJ. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol. 2010;105:289-297.
-
- Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis. 2002;8:244-250.
-
- Papamichael K, Gils A, Rutgeerts P, et al. Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse. Inflamm Bowel Dis. 2015;21:182-197.
-
- Mesonero F, Castro-Poceiro J, Benitez JM, et al. Effectiveness and safety of methotrexate monotherapy in patients with Crohn's disease refractory to anti-TNF-α: results from the ENEDIA registry. Aliment Pharmacol Ther. 2021; https://doi.org/10.1111/apt.16315.
-
- Khanna R, Ma C, Jairath V, Vande Casteele N, Zou G, Feagan BG. Endoscopic assessment of inflammatory bowel disease activity in clinical trials. Clin Gastroenterol Hepatol. 2020; in press. https://doi.org/10.1016/j.cgh.2020.12.017
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical